Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Study of TAU-284 in Paediatric Patients With Perennial Allergic Rhinitis

Next Previous
X
Search
Trial Profile

A Long-Term Study of TAU-284 in Paediatric Patients With Perennial Allergic Rhinitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bepotastine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Registrational
  • Sponsors Mitsubishi Tanabe Pharma Corporation

    • Most Recent Events

    • 26 May 2015 Mitsubishi Tanabe received approval for bepotastine [Talion and Talion OD tablets] for additional pediatric allergic diseases (for children at least seven years of age) in Japan. This approval was based on efficacy and safety results from trials conducted in pediatric patients in Japan.
    • 15 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 03 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top